苦参碱治疗重度斑块状银屑病及抑制复发的疗效:单盲随机对照临床试验
该单盲随机对照试验纳入67例重度斑块状银屑病患者,比较静脉苦参碱与阿维A治疗8周并随访至32周。两组PASI 50无显著差异,但苦参碱组32周复发率显著更低,代谢异常患者减少,不良反应发生率显著低于阿维A组。
要点
- 苦参碱8周治疗重度斑块状银屑病疗效与阿维A相当。
- 苦参碱32周复发率显著低于阿维A,且不良反应更少。
- 苦参碱组代谢异常患者数减少,阿维A组则增加。
核心结论
- 静脉苦参碱可有效改善重度斑块状银屑病,且不良反应轻微。
研究设计与样本
- 单盲随机对照临床试验,共67例患者随机接受苦参碱注射液(0.6 g/日,8周)或阿维A胶囊(0–2周0.75 mg/kg/日,3–8周20–30 mg/日),随访24周。
主要发现
- 苦参碱或阿维A治疗8周均显著降低PASI评分、皮肤分类分级和DLQI评分(P < 0.001)。
- 苦参碱组与阿维A组在PASI 50方面无显著差异。
- 第32周时苦参碱组复发率显著低于阿维A组(P < 0.001)。
- 阿维A组代谢异常患者数增加,而苦参碱组显著减少。
- 苦参碱组不良反应发生率显著低于阿维A组(P < 0.001)。
关键数值与推荐
- 主要终点为第32周达到PASI 50的患者百分比。
- 次要终点包括皮肤分类分级和DLQI评分。
临床怎么用
- 苦参碱可作为重度斑块状银屑病的治疗选择,尤其关注其降低复发和代谢异常的优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drugs that are currently used in the treatment of psoriasis are associated with drawbacks such as rapid recrudescence, high costs and unwanted side-effects. Oxymatrine has a long history of clinical use in the treatment of hepatitis and cancer in China. OBJECTIVES: To explore the efficacy and safety of intravenous oxymatrine in patients with severe plaque psoriasis. METHODS: A total of 67 patients were randomly allocated to receive oxymatrine injections (0.6 g per day for 8 weeks) or acitretin capsules (0.75 mg kg-1 per day from week 0 to week 2 and 20-30 mg per day from week 3 to week 8) and followed up for another 24 weeks. The primary end point was the percentage of patients with ≥ 50% reduction of Psoriasis Area and Severity Index (PASI 50) at week 32. The secondary end points included the skin classification grade and the Dermatology Quality of Life Index (DLQI) score. Side-effects were recorded throughout the whole study to assess the safety profile. RESULTS: Treatment with oxymatrine or acitretin for 8 weeks significantly decreased PASI score, skin classification grade and DLQI score (P < 0.001), with no significant differences between the oxymatrine and acitretin groups in terms of PASI 50. However, at week 32, the relapse rate in the oxymatrine group was significantly lower than that of the acitretin group (P < 0.001). Moreover, while there was an increase in the number of patients with metabolic abnormalities in the acitretin group, a significant reduction was observed in the oxymatrine group. Furthermore, rates of adverse reactions were significantly decreased in the oxymatrine group compared with that of the acitretin group (P < 0.001). CONCLUSIONS: Treatment with oxymatrine effectively ameliorated severe plaque psoriasis, and was accompanied by only minor adverse effects.
引用
- Zhou H, Shi HJ, Yang J, et al. Efficacy of oxymatrine for treatment and relapse suppression of severe plaque psoriasis: results from a single-blinded randomized controlled clinical trial. Br J Dermatol. 2017. PMID: 28112799. doi:10.1111/bjd.15316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。